The impact of bariatric and metabolic surgery on cancer development
Obesity (BMI ≥ 30 kg/m2) with related comorbidities such as type 2 diabetes mellitus, cardiovascular disease, sleep apnea syndrome, and fatty liver disease is one of the most common preventable risk factors for cancer development worldwide. They are responsible for at least 40% of all newly diagnose...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.918272/full |
| _version_ | 1828363843808526336 |
|---|---|
| author | Fabian Lunger Fabian Lunger Pauline Aeschbacher Philipp C. Nett Georgios Peros |
| author_facet | Fabian Lunger Fabian Lunger Pauline Aeschbacher Philipp C. Nett Georgios Peros |
| author_sort | Fabian Lunger |
| collection | DOAJ |
| description | Obesity (BMI ≥ 30 kg/m2) with related comorbidities such as type 2 diabetes mellitus, cardiovascular disease, sleep apnea syndrome, and fatty liver disease is one of the most common preventable risk factors for cancer development worldwide. They are responsible for at least 40% of all newly diagnosed cancers, including colon, ovarian, uterine, breast, pancreatic, and esophageal cancer. Although various efforts are being made to reduce the incidence of obesity, its prevalence continues to spread in the Western world. Weight loss therapies such as lifestyle change, diets, drug therapies (GLP-1-receptor agonists) as well as bariatric and metabolic surgery are associated with an overall risk reduction of cancer. Therefore, these strategies should always be essential in therapeutical concepts in obese patients. This review discusses pre- and post-interventional aspects of bariatric and metabolic surgery and its potential benefit on cancer development in obese patients. |
| first_indexed | 2024-04-14T05:06:29Z |
| format | Article |
| id | doaj.art-66b608e7658549c6a6705ded4ff8ac40 |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-04-14T05:06:29Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-66b608e7658549c6a6705ded4ff8ac402022-12-22T02:10:40ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2022-07-01910.3389/fsurg.2022.918272918272The impact of bariatric and metabolic surgery on cancer developmentFabian Lunger0Fabian Lunger1Pauline Aeschbacher2Philipp C. Nett3Georgios Peros4Department for Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, SwitzerlandDepartment of Visceral and Thoracic Surgery, Cantonal Hospital of Winterthur, Winterthur, SwitzerlandDepartment for Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, SwitzerlandDepartment for Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Bern, SwitzerlandDepartment of Visceral and Thoracic Surgery, Cantonal Hospital of Winterthur, Winterthur, SwitzerlandObesity (BMI ≥ 30 kg/m2) with related comorbidities such as type 2 diabetes mellitus, cardiovascular disease, sleep apnea syndrome, and fatty liver disease is one of the most common preventable risk factors for cancer development worldwide. They are responsible for at least 40% of all newly diagnosed cancers, including colon, ovarian, uterine, breast, pancreatic, and esophageal cancer. Although various efforts are being made to reduce the incidence of obesity, its prevalence continues to spread in the Western world. Weight loss therapies such as lifestyle change, diets, drug therapies (GLP-1-receptor agonists) as well as bariatric and metabolic surgery are associated with an overall risk reduction of cancer. Therefore, these strategies should always be essential in therapeutical concepts in obese patients. This review discusses pre- and post-interventional aspects of bariatric and metabolic surgery and its potential benefit on cancer development in obese patients.https://www.frontiersin.org/articles/10.3389/fsurg.2022.918272/fullBariatric surgerycancer riskmetabolic surgerysleeve gastectomyroux en y gastric bypass |
| spellingShingle | Fabian Lunger Fabian Lunger Pauline Aeschbacher Philipp C. Nett Georgios Peros The impact of bariatric and metabolic surgery on cancer development Frontiers in Surgery Bariatric surgery cancer risk metabolic surgery sleeve gastectomy roux en y gastric bypass |
| title | The impact of bariatric and metabolic surgery on cancer development |
| title_full | The impact of bariatric and metabolic surgery on cancer development |
| title_fullStr | The impact of bariatric and metabolic surgery on cancer development |
| title_full_unstemmed | The impact of bariatric and metabolic surgery on cancer development |
| title_short | The impact of bariatric and metabolic surgery on cancer development |
| title_sort | impact of bariatric and metabolic surgery on cancer development |
| topic | Bariatric surgery cancer risk metabolic surgery sleeve gastectomy roux en y gastric bypass |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2022.918272/full |
| work_keys_str_mv | AT fabianlunger theimpactofbariatricandmetabolicsurgeryoncancerdevelopment AT fabianlunger theimpactofbariatricandmetabolicsurgeryoncancerdevelopment AT paulineaeschbacher theimpactofbariatricandmetabolicsurgeryoncancerdevelopment AT philippcnett theimpactofbariatricandmetabolicsurgeryoncancerdevelopment AT georgiosperos theimpactofbariatricandmetabolicsurgeryoncancerdevelopment AT fabianlunger impactofbariatricandmetabolicsurgeryoncancerdevelopment AT fabianlunger impactofbariatricandmetabolicsurgeryoncancerdevelopment AT paulineaeschbacher impactofbariatricandmetabolicsurgeryoncancerdevelopment AT philippcnett impactofbariatricandmetabolicsurgeryoncancerdevelopment AT georgiosperos impactofbariatricandmetabolicsurgeryoncancerdevelopment |